uniQure stock falls after FDA feedback on gene therapy application
Source: SeekingAlpha
2025-11-03 10:59:15 ET
More on uniQure
- uniQure: 3-Year Huntington's Data Move AMT-130 From 'Promising' To 'Probable' (Rating Upgrade)
- uniQure: Further Upside Likely As The Opportunity Becomes Better Understood
- uniQure: Positive 3-Year AMT-130 Data Leads To Pre-BLA FDA Meeting And Beyond
- uniQure announces pricing of upsized $300M public offering
- uniQure succeeds in pivotal trial for one-time Huntington’s disease therapy
Read the full article on Seeking Alpha
For further details see:
uniQure stock falls after FDA feedback on gene therapy application
uniQure N.V.
NASDAQ: QURE
QURE Trading
12.32% G/L:
$28.18 Last:
1,923,430 Volume:
$28.61 Open:
QURE Latest News
May 05, 2026 07:05:00 am
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
QURE Stock Data
$1,555,111,367
59,307,892
N/A
61
N/A
Biotechnology & Life Sciences
Healthcare
NL
Amsterdam
